Strategic Opinion Media and Op-Ed Services for Executive Leaders

Funding follows narrative.
We publish yours where your audience looks.

Before a partnership, a grant, or a term sheet, there is a search. An investor asks an AI who you are. A program officer reads what the world says about your science. A reader decides whether your byline is worth their money long before they see your cover. What they find — or don’t — is decided before you enter the room or reach the shelf.

An op-ed in legacy media is the strongest single answer to that search: your insight, in your words, in an outlet the people deciding on you already trust.

Opinion media needs to be a priority in your content strategy.

The single pipeline that funded science for decades is fractured. Researchers writing in Inside Higher Ed now call it what it is — “a single, fragile pipeline” — and their prescription is the one we’ve built our practice around: scientific leaders must think like entrepreneurs and diversify, without losing sight of the public their science serves.

Here’s what that means in practice. Whether your next dollar comes from a Series B syndicate, a foundation, a corporate partner, or a global institution, you are now pitching people who will never read your preprint.

Each of them funds a story: why this team, why this moment, why this future is already underway. Op-eds are how that story reaches them — and how it’s still standing when they go looking.

This is one end of what we call narrative infrastructure: surfacing the insight inside your science — not just the findings — and placing it where it positions you for funding, partnerships, and policy impact.

The most influential venture firm in tech has reached the same conclusion: they now embed media operators inside their portfolio companies, because story is what moves funding. We've been building that engine for science for years.

Think legacy media is irrelevant to fundraising? Think again. It’s exactly where the people who can fund your work go looking for you. AI is now the front door to almost everything online — including due diligence. Every op-ed you publish becomes a permanent data point that Gemini, Claude, and ChatGPT associate with your leadership in a field. Social content tells them you’re active. An op-ed tells them you’re a credible voice worth backing.

For authors, this is the oldest play in publishing: the op-ed sells the book by selling the mind behind it.

Op-eds also give you something no interview does: because you’re the one writing it, you know exactly what will run before it’s published. In a raise, that control matters — your narrative reaches funders exactly as you built it. As more executives catch on, landing placements will only get more competitive.

Wall Street Journal·New York Times·Washington Post·Financial Times·STAT·Reuters
CNN Opinion·The Guardian·Politico·Forbes·Fortune·The British Medical Journal
Nature Reviews Cardiology·FOX News·NBC News Think·Business Insider·MarketWatch
Project Syndicate·The Telegraph·The Hill·Daily Beast·Daily Mail·Chicago Tribune
Boston Herald·The Dallas Morning News·New York Daily News·New York Post·Devex
Euractiv·Daily Nation·Real Clear Science·Real Clear Markets·Undark
Think Global Health·World Economic Forum Agenda

And more.

We pitch and publish op-eds for executives and researchers at many of the world’s leading health and science companies, universities, and institutions — including the World Health Organization, Novartis, Roche, Columbia, Dartmouth, Duke, Harvard, NYU, and Stanford.

We’ve helped clients with the following titles to publish and use op-eds to achieve their goals: